GuidelineCurrent
AGIHO 2024 update — 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin in adult neutropenic patients with solid tumours and hematological malignancies
AGIHO / German Society of Hematology and Medical Oncology, 2025
Febrile neutropenia is an oncologic emergency requiring prompt risk stratification, diagnostic sampling without delaying therapy, immediate empiric antibacterial treatment in high-risk patients, epidemiology- and resistance-informed escalation/de-escalation, and a structured approach to persistent fever and empirical or pre-emptive antifungal treatment.
Conditional recommendationModerate certainty
View source guidelineClinical Context & Relevant Topics (2)
Disease ReferenceFebrile Neutropenia & Neutropenic Sepsis
Time-critical ICU management of fever and organ dysfunction during neutropenia, with early antipseudomonal therapy and source-directed escalation.
View Topic Context →
Immunocompromised & Oncologic Critical Illness
Host immune defects, neutropenic sepsis, acute respiratory failure (PJP/Aspergillus), tumor lysis syndrome, leukostasis, CAR-T CRS/ICANS, and ICU triage.
View Topic Context →